<DOC>
	<DOCNO>NCT02602067</DOCNO>
	<brief_summary>Tenatumomab Sigma-Tau develop new anti-Tenascin antibody . It murine monoclonal antibody direct towards Tenascin-C. By mean antibody , Tenascin-C expression study commercial tissue array slide carry malignant breast , colorectal , lung , ovarian B T cell Non-Hodgkin Limphoma tissue section . All cancer type show positivity Tenascin-C 64 % 13.3 % . Consequently , Sigma-tau explore use 131I-labeled Tenatumomab anti-cancer radioimmunotherapy .</brief_summary>
	<brief_title>131Iodine-Tenatumomab Treatment Tenascin-C Positive Cancer Patients</brief_title>
	<detailed_description>This open-label dose escalation study . The study conduct two step : 1 . STEP A aims identify optimal amount antibody convey specific radio-label activity radionuclide . 2 . STEP B conduct amount antibody choose STEP A , escalate radio-labeled therapeutic dose response curve perform ( 3.5 5.5 GBq ) A maximum 36 evaluable patient suffer treatment-refractory Tenascin-C positive tumor . This dose escalation study evaluate use descriptive statistic : sample size calculation perform Primary objective 1 . To identify Maximum Tolerated Dose ( MTD ) ass Safety Tolerability i.v . infused 131I-Tenatumomab . 2 . To identify optimal amount unlabeled Tenatumomab able convey 131I- Tenatumomab high Tumor/nonTumor ratio . 3 . To evaluate whole body Dosimetry ( safety dosimetry ) Tumor normal tissue ratio ( T/nT ratio , refer AUC ) i.v.infused 131I-Tenatumomab . 4 . To evaluate intra-lesional distribution retention 131I-Tenatumomab record individual lesion dosimetry . 5 . To evaluate systemic biodistribution , pharmacokinetics , urinary excretion dose linearity 131I-Tenatumomab . Secondary objective 1 . To evaluate proportional 131I-Tenatumomab tumor binding , function total load . 2 . To evaluate Pharmacokinetics Tenatumomab ( protein protein related material ) serum . 3 . To evaluate preliminary Efficacy 131I-Tenatumomab base disease response rate ( Complete Response , Partial Response , Stable Disease ) patient 's general clinical condition ECOG performance status assessment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Urogenital Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Respiratory Tract Neoplasms</mesh_term>
	<mesh_term>Soft Tissue Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Connective Soft Tissue</mesh_term>
	<criteria>1 . Written informed consent . 2 . A patient ( ) histologically document advanced tumor relapse , refractory , standard treatment standard treatment available ( b ) confirm TenascinC expression obtain biopsy least one reachable tumor lesion . These patient fail one prior therapeutic line assessable measurable disease expression , consider eligible standard approach curative intent , assess Investigator . 3 . Agreement hemopoietic stem cell collection procedure ( procedure perform upon clinical evaluation Investigator deem necessary interest patient ) . 4 . Male female ≥18 year age 5 . Eastern Cooperative Oncology Group ( ECOG ) , WHO performance status ≤ 2 Karnofsky &gt; 60 6 . Life expectancy least 3 month . 7 . Negative pregnancy test woman childbearing potential . Appropriate contraception ( one highly effective method combination acceptable method ) use study period 90 day last followup visit ( End Study Visit ) 8 . Hematological , thyroid , liver , cardiac renal function test result ≤ grade 2 toxicity ( accord US National Cancer Institute 's `` Common Terminology Criteria Adverse Events v4.03 [ CTCAE ] '' ) , e.g . : Haematology : Hematocrit ≥ 30 % Hemoglobin ≥ 9.0 g/dl White blood cell count ≥ 3 x 109/L Neutrophils &gt; 1.5 x109/L Platelets ≥ 100x 109/L Thyroid : FreeTriiodothyronine FreeThyroxine ≤ 3 time upper limit normal &gt; 3 time low limit normal . Liver : Alanine transaminase , Aspartate transaminase , Alkaline Phosphatase ≤ 2.5 time institutional upper limit normal ( ULN ) ≤5 x ULN presence liver metastasis . Bilirubin ≤ 1.5 x ULN ≤3 x ULN presence liver metastasis . Renal : Urine protein : ≤30 mg/dl dipstick : ≤3 eGFR≥60 ml/min/1.73 m2 ( Chronic kideny diseaseEpidemiology collaboration formula ) Cardiac • Resting Ejection Fraction ( EF ) ≥ 50 % 1 . Known hypersensitivity Tenatumomab , Iodine excipient . 2 . Active infection screen history severe infection within previous 2 month , consider clinically relevant Investigator . 3 . Positive test Human Immunodeficiency Virus ( HIV ) and/or chronically active Hepatitis B C. 4 . Patients primary Central nervous system tumor cerebral metastasis . 5 . Administration another investigational medicinal product within 45days screening period . 6 . Previous treatment radiopharmaceutical within period correspond 8 halflives radionuclide use prior administration study drug . 7 . History somatic psychiatric disease/condition may interfere objective study . 8 . Major illness , trauma , surgery within 2 week screen period , consider clinically significant Investigator . 9 . Patient underwent chemotherapy and/or radiation therapy and/or treatment biologics ( murine origin ) within 4 week screen period . 10 . Women breast feeding , due potential risk damage infant . 11 . Men unwilling use appropriate contraceptive method study 90 day last followup visit ( End Study Visit ) . 12 . Bladder catheterization perform , patient unwilling catheterize necessary . 13 . Murine antibody treat patient . It discretion Investigator exclude patient worsen considerably screen Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>